Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2008-05-06
2008-05-06
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S189100, C530S324000, C530S328000
Reexamination Certificate
active
07368118
ABSTRACT:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
REFERENCES:
patent: 3645852 (1972-02-01), Axen et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4428941 (1984-01-01), Galibert et al.
patent: 4487715 (1984-12-01), Nitecki et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4935235 (1990-06-01), Rutter et al.
patent: 5017558 (1991-05-01), Vyas
patent: 5019386 (1991-05-01), Machida et al.
patent: 5039522 (1991-08-01), Neurath
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5133961 (1992-07-01), Ellis et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5158769 (1992-10-01), Neurath et al.
patent: 5780036 (1998-07-01), Chisari
patent: 5788969 (1998-08-01), Chisari
patent: 5840303 (1998-11-01), Chisari et al.
patent: 5932224 (1999-08-01), Chisari
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6322789 (2001-11-01), Vitiello et al.
patent: 6607727 (2003-08-01), Chisari et al.
patent: 2003/0171538 (2003-09-01), Chisari
patent: 013 828 (1980-08-01), None
patent: 105 481 (1984-04-01), None
patent: 271 302 (1987-12-01), None
patent: 293 201 (1988-11-01), None
patent: 326 111 (1989-01-01), None
patent: 327369 (1989-08-01), None
patent: 431 327 (1991-06-01), None
patent: 469 281 (1992-02-01), None
patent: 534 615 (1993-03-01), None
patent: 2034323 (1980-06-01), None
patent: 161999 (1985-08-01), None
patent: 64-025800 (1989-01-01), None
patent: WO 92/00753 (1992-01-01), None
patent: WO 93/03753 (1993-03-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/25060 (1994-11-01), None
patent: WO 95/03777 (1995-02-01), None
patent: WO 95/04817 (1995-02-01), None
Nayersina R. et al “HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.” J Immunol. May 15, 1993;150(10):4659-71.
Bertoletti, A. et al. “Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells”Nature, Jun. 2, 1994, 369:407-410.
Bichko et al, “Subtype ayw variant of hepatitis B virus”FEBS Lett., 1985, 185:208-212.
Bowie et al. “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science, 1990, 247:1306-1310.
Carbone et al. “Induction of Cytotoxic T Cells by Primary in vitro Stimulation with Peptides”J. Exp. Med., 1988, 167:1767-1779.
De Magistris, M.T. et al. “Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor”Cell, Feb. 21, 1992, 68(4):625-634.
Falk et al. “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules”Nature, May 1991, 351:290-296.
Galibert et al. “Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned inE. coli” Nature, 1979, 281:646-650.
Hilleman “Comparative Biology and Pathogenesis of AIDS and Hepatitis B Viruses: Related but Different”AIDS Res. Hum. Retrovir., 1994, 10:1409-1419.
Jameson, S.C. et al. “Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells”J. Exp. Mod., Jun. 1, 1993, 177(6):1541-1550.
Kumar et al. “Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties”PNAS USA, 1990, 87:1337-1341.
Lewin “When Does Homology Mean Something Else?”Science, 1987, 237:1570.
Milich et al. “Immune Response to Hepatitis B Virus Core Antigen (HBcAg): Localization of T Cell Recognition Sites Within HBcAg/HBeAg”J. Immunol., 1987, 139:1223-1231.
Nayersina et al. “HLA A2 Restricted Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes during Hepatitis B Virus Infection”J. Immunol., 1991, 150:4659-4671.
Reeck et al. “Homology in Proteins and Nucleic Acids: A Terminology Muddle and a Way out it”Cell, 1987, 50:667.
Ruppert, J. et al. “Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules”Cell, 1993, 74(5):929-937.
Tong et al. “Active Hepatitis B Virus Replication in the Presence of Anti-HBe is Associated with Viral Variants Containing an Inactive Pre-C Region”Virology, 1990, 176:596-603.
Vitiello, A et al. “Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans”J. of Clin. Invest., Jan. 1995, 95(1):341-349.
Greenstein, J.L. et al. “A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120”J. Immunology, 1992, 148:3970-3977.
Watari, E. et al. “A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2”J. Exp. Med., 1987, 165(2):459-470.
Hopp, T.P. “Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier”Mol. Immunol., 1984, 21(1):13-16.
Bessler, W.G. et al. “The synthetic analog of bacterial lipoprotein are potent immunoadjuvants in combination with or covalently linked to antigen”Prog. Leukocyte Biol., 1986, 5:337-344.
Parker et al. “Peptide Binding to HLA-A2 and HLA-B27 Isolated froE. coli” J. Biol. Chem., 1992, 267:5451-5459.
Penna et al, “Cytotoxic T Lymphocytes Recognize an HLA-A2-restricted Epitope within the Hepatitis B Virus Nucleocapsid Antigen”Exp. Med., 1991, 174:1565-1570.
Ferrari et al. “Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen”J. Clin. Invest., 1991, 88:214-222.
Roitt et al. “Immunology”, 3rdEd., Mosby, St. Louis, p. 4.14, 1993.
Rehermann et al. “The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis”J. Exp. Med., Mar. 1, 1995, 181(3):1047-1058.
Zinkernagel et al. “The Lymphoreticular System in Triggering Virus Plus Self-Specific Cytotoxic T Cells: Evidence for T Help”J. Exp. Med., 1978, 147:897-911.
Von Boehmer et al. “Distinct Ir Genes for Helper and Killer Cells in the Cytotoxic Response to H-Y Antigen”J. Exp. Med., Nov. 1979, 150:1134-1142.
Melief et al. “Cooperating Between Subclasses of T Lymphocytes in the in vitro Generation of Cytotoxicity Against a Mutant H-2K Difference an Analysis with Anti-Lyt Antisera”Eur. J. Immunol, 1979, 9:7-12.
Widmer et al. “Antigen-derived helper cell-independent cloned cytolytic T lymphocytes”Nature, 1981, 294:750-752.
Lerner et al. “Chemically synthesized peptides predicted form the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles”Proc. Natl. Acad. Sci. USA, Jun. 1981, 78:3403-3407.
Bhatnagar et al. “Immune response to synthetic peptide analogues of hepatitis B surface antigen specific for the determinant”PNAS USA, Jul. 1982, 79:4400-4404.
Mondelli et al. “Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes”J. Immunol., Dec. 1982, 129:2773-2778.
Von Boehmer et al. “Autonomously proliferating K/D-restricted cytolytic T cell clones”Eur. J. Immunol., 1983, 12:176-179.
Neurath et al. “Specificity of antibodies elicited by a synthetic p
Campell Bruce R.
Peng Bo
Saliwanchik Lloyd & Saliwanchik
The Scripps Research Institute
LandOfFree
Peptides for inducing cytotoxic T lymphocyte responses to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for inducing cytotoxic T lymphocyte responses to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for inducing cytotoxic T lymphocyte responses to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2812725